anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
To assess the correlation between serum fibroblast growth factor 23 (FGF-23)/Klotho levels and end-stage renal disease (ESRD) in middle-aged and elderly patients combined with low bone mineral density (BMD). The BMD of the lumbar vertebrae and femoral neck of 87 patients with ESRD was measured using a dual-energy X-ray bone densitometer during hospitalisation and the patients were divided into a normal bone mass group and a low bone mass group. Haemoglobin, albumin, urea nitrogen, uric acid, creatinine, low-density lipoprotein cholesterol, alkaline phosphatase, blood calcium, blood phosphorus and full parathyroid hormone were detected using an automatic biochemical analyser. The levels of serum FGF-23, Klotho and activated vitamin D in the patients with ESRD were measured via an enzyme-linked immunosorbent assay. Older age and decreased serum creatinine levels and serum Klotho levels were associated with low bone mass. There were significantly more men in normal bone mass group (n=49, 74.24%) than in low bone mass group (n=8, 38.10%). The correlation analysis showed that BMD was negatively correlated with age but positively correlated with serum Klotho. The binary logistic regression analysis indicated that old age and the decrease in serum Klotho level were independent risk factors of a low BMD (all p<0.05). In conclusion, serum Klotho is closely related to BMD changes in middle-aged and elderly patients with ESRD. A high Klotho level is a protective factor and is expected to be a marker in reducing bone mineral metabolism disorders and improving the prognosis of patients with ESRD.
N=10 patients that have had no prior treatment with biological agents that block TNF will receive a total of 13 X 400mg subcutaneous injections of bermekimab. Dosing will occur weekly for 12 weeks, inclusive of visit 1 and visit 13.
AIM: To analyse data from the All of Us Research Program to evaluate the real-world application and long-term effectiveness of semaglutide in treating type 2 diabetes and obesity patients in a large population.
MATERIALS AND METHODS: We identified patients prescribed semaglutide and analysed differences in route of administration and the time on semaglutide. For individuals diagnosed with obesity, we measured changes in body mass index (BMI) and weight from baseline, while measured changes in HbA1c for those patients with type 2 diabetes. We also examined the occurrence of newly diagnosed common adverse events from taking semaglutide.
RESULTS: For 3739 semaglutide patients, those on injectable semaglutide (3364 patients) averaged 301.54 days on the medication, with 20.36% having no end date, while those on oral semaglutide (435 patients) averaged 172.48 days, with 24.60% having no end date. We found average decreases of 1.54 kg/m2 in BMI, 4.65 kg in weight and 0.75% in HbA1c for semaglutide users. The decreases were larger in participants taking injectable formulation, probably because of higher starting values. Over time, improvements in these outcomes diminished, but the values remained significantly lower than baseline levels. Approximately only 1.0% of patients reported newly diagnosed common adverse events.
CONCLUSIONS: Consistent with clinical trial findings, this real-world data analysis showed that semaglutide was well tolerated and that, for a large population, it effectively reduced BMI, body weight and HbA1c, albeit to smaller magnitudes than observed in clinical trials. These findings provide valuable insights into real-world experience and the long-term effectiveness of semaglutide.
Celecoxib capsule is a nonsteroidal anti-inflammatory drug, available as capsules containing 50 mg, 100 mg, 200 mg and 400 mg celecoxib USP for oral administration. The chemical name is 4-[5-(4-methylphenyl)- 3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide and is a diaryl-substituted pyrazole. The molecular weight is 381.38. Its molecular formula is C17H14F3N3O2S, and it has the following chemical structure:  
  
  
  
Celecoxib is a white or almost white crystalline powder with a pKa of 11.1 (sulfonamide moiety). Celecoxib is soluble to freely soluble in ethanol, soluble in methylene chloride and practically insoluble in water.  
  
The inactive ingredients in celecoxib capsules include: crospovidone, hydroxypropyl cellulose, lactose monohydrate, povidone, sodium lauryl sulfate, sodium stearyl fumarate. The empty hard gelatin capsule shells contain gelatin and titanium dioxide. The capsules are imprinted with edible ink containing propylene glycol and shellac. In addition, 50 mg capsules are imprinted with FD&C Red #40 aluminum lake and sodium hydroxide. 100 mg capsules are imprinted with FD & C Blue # 2 aluminum lake and strong ammonia solution. 200 mg capsules are imprinted with strong ammonia solution and yellow iron oxide. 400 mg capsules are imprinted with FD & C Blue # 2 aluminum lake, strong ammonia solution and yellow iron oxide.
Corneal neovascularization (CNV) is one of the common blinding factors worldwide, leading to reduced vision or even blindness. However, current treatments such as surgical intervention and anti-VEGF agent therapy still have some shortcomings or evoke some adverse effects. Recently, SU6668, an inhibitor targeting angiogenic tyrosine kinases, has demonstrated growth inhibition of neovascularization. But the hydrophobicity and low ocular bioavailability limit its application in cornea. Hereby, we proposed the preparation of SU6668 pure nanoparticles (NanoSU6668; size ~135 nm) using a super-stable pure-nanomedicine formulation technology (SPFT), which possessed uniform particle size and excellent aqueous dispersion at 1 mg/mL. Furthermore, mesenchymal stem cell membrane vesicle (MSCm) was coated on the surface of NanoSU6668, and then conjugated with TAT cell penetrating peptide, preparing multifunctional TAT-MSCm@NanoSU6668 (T-MNS). The T-MNS at a concentration of 200 µg/mL was treated for CNV via eye drops, and accumulated in blood vessels with a high targeting performance, resulting in elimination of blood vessels and recovery of cornea transparency after 4 days of treatment. Meanwhile, drug safety test confirmed that T-MNS did not cause any damage to cornea, retina and other eye tissues. In conclusion, the T-MNS eye drop had the potential to treat CNV effectively and safely in a low dosing frequency, which broke new ground for CNV theranostics.
An advisor can provide proactive, efficient service to clients through the use of the present group management system (fig. 5). The system is an effective work management tool that efficiently organizes an advisor's day-to-day operations, work flow, clients and prospects. To allow coordinated consultation based not only on an individual's demographic information, but also on the individual's relationships to others, people and organizations are arranged into client groups and prospect groups. An advisor can analyze an individual's relationship with his/her family, business and pension to provide overall financial planning and security. The group management system includes numerous innovative, coordinated features including security measures, an easily accessible FRONT PANEL (65), a simplified SEARCH ENGINE (84), and the ability to refresh data. The grouping of clients in the CARD FILE (82) enables the DRAG and DROP function (460-478) to initialize applications without the need for repeated input of data. The REFRESH, ON-LINE CLIENT DATA (158), FIELD DATA CAPTURE and EXPORT features allow communication with a host database or other local databases.
PURPOSE:The titled pharmaceutical, obtained by forming a high polymer layer capable of exhibiting tackiness at ordinary temperature on a carrier having flexibility, and incorporating or applying bleomycin hydrochloride, etc. exhibiting remarkable effect on skin cancer, etc. to the layer, and capable of suppressing side effects of the above-mentioned chemical by percutaneous administration. CONSTITUTION:A tape pharmaceutical, obtained by forming a high polymer layer which is preferably a copolymer of (a) 50-99wt% (meth)acrylic acid ester having a 4-14C alkyl group and (b) 1-50wt% at least one monomer copolymerizable with the above-mentioned ester having tackiness at ordinary temperature, and incorporating or applying bleomycin hydrochloride (or sulfate) exhibiting remarkable effect on dermal malignant tumors, e.g. epithelial cancer or melanoma, to the above-mentioned layer, and capable of treating by direct application to the integument of local diseases with percutaneous absorption of the above-mentioned chemical. A constant amount of the above-mentioned chemical can be percutaneously administered without loss by the above-mentioned pharmaceutical, and improved remedial effect can be exhibited without side effects.
The present invention discloses a novel purpose of sodium polyacrylate and carboxymethylcellulose grafted polyacrylic acid which are used for preparing a hemostatic. The hemostatic is used for the hemostasis of the hemorrhage of blood vessels, comprising arteries and veins in large sizes, middle sizes and small sizes in the conditions of wounds, war wounds and operation wounds, and the preparation of the hemostatic is single or mixed. The hemostatic prepared from the sodium polyacrylate and the carboxymethylcellulose grafted polyacrylic acid has the advantages of high speed of the hemostasis and good effect. When the femoral artery of a flap-eared rabbit is incised in a lateral direction for 3/4, the hemorrhage of the blood vessel can be stopped effectively in 30 seconds, and no death occurs in all cases. The preparation is safe and non-toxic, no heat is produced in the process of the hemostasis, and the use is convenient. The hemostatic can be applied directly or applied with the adoption of other packing forms.
The invention relates to the field of medicine and, more specifically, to the development of a pharmaceutical composition containing protein NMB0873. Said composition provides protection against different diseases which may or may not be caused by pathogens. The NMB0873 protein was identified as a component of Neisseria meningitidis outer membrane vesicle (OMV) preparations and obtained using recombinant deoxyribonucleic acid (DNA) technology. Furthermore, the immunogenicity and protective activity thereof were evaluated in animal models. Owing to the high level of conservation of the gene that codes for the NMB0873 protein, the composition containing same has a high value as an antigen that can induce an immune response with broad reactivity. The composition is suitable for use in human medicine.
Percent necrosis (PN) following chemotherapy is a prognostic factor for survival in osteosarcoma. Pathologists estimate PN by calculating tumor viability over an average of whole-slide images (WSIs). This non-standardized, labor-intensive process requires specialized training and has high interobserver variability. Therefore, we aimed to develop a machine-learning model capable of calculating PN in osteosarcoma with similar accuracy to that of a musculoskeletal pathologist. In this proof-of-concept study, we retrospectively obtained six WSIs from two patients with conventional osteosarcomas. A weakly supervised learning model was trained by using coarse and incomplete annotations of viable tumor, necrotic tumor, and nontumor tissue in WSIs. Weakly supervised learning refers to processes capable of creating predictive models on the basis of partially and imprecisely annotated data. Once "trained," the model segmented areas of tissue and determined PN of the same six WSIs. To assess model fidelity, the pathologist also estimated PN of each WSI, and we compared the estimates using Pearson's correlation and mean absolute error (MAE). MAE was 15% over the six samples, and 6.4% when an outlier was removed, for which the model inaccurately labeled cartilaginous tissue. The model and pathologist estimates were strongly, positively correlated (r = 0.85). Thus, we created and trained a weakly supervised machine learning model to segment viable tumor, necrotic tumor, and nontumor and to calculate PN with accuracy similar to that of a musculoskeletal pathologist. We expect improvement can be achieved by annotating cartilaginous and other mesenchymal tissue for better representation of the histological heterogeneity in osteosarcoma.
The study aims to validate the gait metrics of the Neural Sleeve in healthy adult volunteers. All participants will wear a Neural Sleeve on their dominant leg. The Zeno pressure gait mat will be laid flat on the ground and used for all walking conditions. Overall, participants will perform three, 5 minute walking bouts without electrical stimulation. Two walking conditions will be performed while wearing the Neural Sleeve, however, no electrical stimulation will be utilized. The movement sensors on the Neural Sleeve will collect motion data that permits the comparison of gait metrics from the Sleeve to those measured by the gait mat. During the walking trials participants will be told that they can take a break if needed. Condition order will be randomized and participants will be offered 5 minutes of rest between consecutive trials. Validity of gait metrics of the Neural Sleeve will be compared against the Zeno walkway.
BACKGROUND: Growth and differentiation factor 15 (GDF15) has been proved to regulate the process of Myocardial ischemia-reperfusion injury (MIRI), which is a serious complication of reperfusion therapy. The present study aimed to explore if GDF15 could regulate the MIRI-induced ferroptosis.
METHOD: MIRI animal model was established by ligating the left anterior descending coronary artery. Oxygen-glucose deprivation/reoxygenation (OGD/R) cell model was established to imitate MIRI in vitro. The indicators of ferroptosis including mitochondrial damage, GPX4, FACL4, XCT4, and oxidative stress markers were evaluated.
RESULTS: Overexpression of GDF15 greatly inhibited MIRI, improved cardiac function, alleviated MIRI-induced ferroptosis. pc-DNA-GDF15 significantly inhibited the oxidative stress condition and inflammation response. The OGD/R-induced ferroptosis was also inhibited by pc-DNA-GDF15.
CONCLUSION: We proved that the MIRI-induced ferroptosis could by inhibited by pc-DNA-GDF15 through evaluating mitochondrial damage, MDA, GSH, and GSSG. Our research provides a new insight for the prevention and treatment of MIRI, and a new understanding for the mechanism of MIRI-induced ferroptosis.
The invention discloses a cloud-assisted decision tree model diagnosis system and method for medical data privacy protection, wherein the system comprises a trusted center, an evaluation server ES, an auxiliary server CS, a medical service provider MP and a patient; assuming a patient P in the system x To obtain a diagnosis of a disease according to the symptoms. The medical service provider possesses a decision tree model trained by medical records, and the trusted center initializes and distributes a provider key, a patient key, an evaluation key and an auxiliary key to the system. By means of said secret key, P x Symptoms are sent to the evaluation server and the MP sends the decision tree to the auxiliary server. And determining the pseudo subscript of the characteristic by using a K nearest neighbor method through random replacement and confusion operation by the server to obtain partial information of the decision path generation diagnosis. In the whole process P x The symptoms of (c) and the decision model of the MP are not revealed, the server does not know the diagnosis. The invention has higher safety by using random permutation and one-way function, and has high decision making speed, light bottom layer processing and practicability.
The prevalence of childhood and adolescent obesity has reached an all-time high. There is a pressing need to better understand the behavioral mechanisms that control appetite and eating in children and to identify children who are most susceptible to overeating in the current obesogenic food environment. Obesogenic environments offer convenient access to large portions of palatable, energy-dense foods. The portion size of foods has been identified as an important determinant of energy intake in adults and children. While portion size effects have been found in heterogenous groups of healthy individuals, some evidence points to possible individual differences in the magnitude of children's responsiveness to large food portions. For example, data from a previous laboratory study suggest that overweight and obese children may be particularly vulnerable to overeating when presented with large food portions. Further, the magnitude of a portion size effect on intake may also depend on how reinforcing (or rewarding) children find food to be. It is possible that the relative reinforcing value of food may interact with environmental cues, such as the portion size of food, to affect children's energy intake when large portions of palatable, energy-dense foods are available. The primary aim of this study is to compare the effects of increasing the portion size of all foods and a beverage served at a meal on energy intake in normal-weight and obese children. A second aim is to test if children who find food very reinforcing relative to an appealing nonfood alternative will show a significantly greater increase in energy intake in response to increasing portion sizes than will children who find food less reinforcing. The findings from this study are expected to extend previous findings to test how environmental factors, such as food portion size, may interact with individual differences in weight status or food reinforcement to affect energy intake in children.
BACKGROUND: Benign prostatic hyperplasia (BPH) is prevalent among elderly men, necessitating focused attention. The Prostatic Urethral Lift (PUL) procedure, a minimally invasive intervention, has emerged as a promising option for BPH management. It has shown remarkable results in ameliorating lower urinary tract symptoms (LUTS), enhancing quality of life, and preserving sexual function. This study aims to evaluate the effectiveness and safety of PUL in BPH patients.
METHODS: Key databases (MEDLINE, Cochrane CENTRAL, ScienceDirect, EBSCO, Google Scholar) were systematically searched using pertinent terms related to PUL and BPH. Following the PRISMA checklist, we considered only randomized controlled trials (RCTs) from 2013 to 2023. The assessment focused on LUTS, quality of life, sexual function, and adverse events within three months. Follow-up post-treatment mean values compared with controls (Sham) and the improvement from baseline to post-treatment follow-up duration were considered. Statistical analysis and risk of bias evaluation were conducted using Review Manager 5.4.1, presenting results as difference of mean values (MD) and risk ratios (RR).
RESULTS: A meta-analysis with a Random Effects Model of 7 RCTs involving 378 confirmed BPH patients demonstrated significant improvements in the PUL arm including International Prostate Symptom Score (IPSS) (MD 5.51, p<0.0001), maximum urinary flow rate (Qmax) (MD 2.13, p=0.0001), BPH Impact Index (BPHII) (MD 2.14, p=0.0001), and IPSS-QoL (MD 1.50, p<0.0001), without significant increase of adverse events (RR 1.51; p=0.50). Positive outcomes were observed in sexual function variables and post-void residual measurements when post-treatment values were compared to baseline.
CONCLUSIONS: PUL holds advantages over control interventions, providing encouraging prospects for BPH management. This study underscores the need for further exploration of PUL's efficacy and safety in BPH patients.
This is a Phase 1, single-center, open -label (all people know the identity of the intervention) study of intranasal esketamine in two cohorts: Cohort 1 will be healthy participants assigned to a fixed treatment sequence and Cohort 2 will be participants with nasal rhinitis randomized to 1 of 2 treatment sequences. For all participants, the study comprises 3 phases: a Screening phase (up to 21 days), an Open Label Treatment phase (includes 2 treatment periods; Period 1 and Period 2) and Follow-up phase (10 +/-2 days after last dose of esketamine).

Total study duration for participants in Cohort 1 is up to 52 days which includes Screening phase, Period 1 (3 days) where participants will self-administer a 56 milligram (mg) intranasal dose of esketamine solution on Day 1 and Period 2 (16 days) where participants will self-administer 200 microgram (mcg) of intranasal mometasone suspension on Day 1 (which will begin immediately following the 30 hour pharmacokinetic sample of Period 1) to Day 15, and then 200 mcg of intranasal mometasone suspension prior to a 56 mg dose of intranasal esketamine solution on Day 16 and the follow-up phase. Total study duration for participants in Cohort 2 is up to 44 days which includes Screening phase, Period 1 and Period 2 each of 3 days with a washout period of 5 to 10 days in-between esketamine dosing, and the follow-up phase. Cohort 2 participants will be randomly assigned to either treatment Sequence 1 or 2, wherein Sequence 1 comprises a 56 mg intranasal dose of esketamine solution alone in period 1 followed by period 2 which comprises a pretreatment with oxymetazoline 0.05 percent (%) weight by volume (w/v) solution 1 hour before administration of a 56 mg intranasal dose of esketamine solution. Sequence 2 comprises of a pretreatment with oxymetazoline 0.05 % w/v solution 1 hour before administration of a 56 mg intranasal dose of esketamine solution in Period 1 followed by period 2 which comprises a 56 mg intranasal dose of esketamine solution alone. Blood samples will be collected for evaluation of pharmacokinetic parameters of intranasal esketamine in healthy participants and participants with allergic rhinitis. Participants' safety will be monitored throughout the study.
The invention relates to the pharmaceutical industry and to medicine, and more particularly to complex polyionic infusion solutions that have a detoxifying effect as a result of antihypoxic, antioxidant and hepatoprotective properties. A preparation can be used to treat intoxications of various origins. The aim of the invention is producing a polyionic infusion solution comprising as an active component meglumine sodium succinate having increased safety due to reducing the content of toxicants and long storage stability. The set aim is solved by that the polyionic infusion solution comprising chlorides of sodium, potassium and magnesium, meglumine sodium succinate as a biologically active component, and water for injections, according to the invention, further comprises a stabilising agent which is a pharmaceutically acceptable carboxylic acid or inorganic acid or a combination thereof, wherein the solution has a pH from 7.0 to 5.5 at the following ratio of components, wt.%: sodium chloride - 0.500-0.700, magnesium chloride - 0.010-0.014, potassium chloride - 0.025-0.035, meglumine sodium succinate - 1.350-1.650, stabilising agent - 0.0014-0.1827, water for injections - the rest. According to the invention, the stabilising agent is a pharmaceutically acceptable carboxylic acid or a combination of acids such as ethylene diamine tetraacetic, ethanoic, 2-hydroxybutanedioic, 2-hydroxy-1,2,3-propane tricarboxylic, butanedioic, trans-butenedioic, 2,3-dihydroxybutanedioic, 2-hydroxypropanoic, carbonic acids. Furthermore, the stabilising agent is a pharmaceutically acceptable inorganic acid or a combination of acids such as hydrochloric, phosphoric, sulphuric acids.